Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilization?
| Autor: | D. Healy, R. Yates, E. Loumaye, Peter Brinsden, Marc Germond, L.M. Bonaventura, T. Strowitzki, C.M. Howles |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
endocrine system medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment Ovary Fertilization in Vitro Biology Growth Hormone-Releasing Hormone Placebo Chorionic Gonadotropin Follicle-stimulating hormone Double-Blind Method Ovarian Follicle Ovulation Induction Internal medicine Follicular phase medicine Humans In vitro fertilisation Rehabilitation Obstetrics and Gynecology female genital diseases and pregnancy complications Somatropin Treatment Outcome Endocrinology medicine.anatomical_structure Reproductive Medicine Female Gonadotropin Hormone |
| Zdroj: | Human Reproduction. 14:1939-1943 |
| ISSN: | 1460-2350 0268-1161 |
| DOI: | 10.1093/humrep/14.8.1939 |
| Popis: | Treatment with growth hormone-releasing factor (GRF) has been reported to improve the ovarian response to gonadotrophins in women who respond poorly to ovarian stimulation during in-vitro fertilization (IVF). The efficacy and tolerability of GRF were studied in a randomized, double-blind, placebo-controlled trial involving 196 patients. Following down-regulation with a gonadotrophin-releasing hormone agonist (GnRHa), patients were randomized to receive GRF (500 microg twice daily; n = 96) or placebo (n = 100) in addition to follicle stimulating hormone (FSH); treatment was continued until human chorionic gonadotrophin was given, or for a maximum of 14 days. GRF had no significant effect on the mean number of follicles with a diameter of >/=16 mm (GRF: 3.26 +/- 2.29; placebo: 3.27 +/- 2.30; P = 0.95), the number of FSH ampoules required to achieve ovarian stimulation (GRF: 55.2 +/- 16. 4; placebo: 54.9 +/- 17.2; P = 0.50), or on secondary measures of ovarian response and treatment outcome. There were, however, significant increases in circulating growth hormone (GH) and insulin-like growth factor (IGF)-1 concentrations. GRF was well tolerated. It is concluded that, despite producing significant increases in GH and IGF-1, concomitant treatment with GRF does not improve the ovarian response to FSH in poorly responsive women undergoing IVF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|